Hot off the ECTRIMS Press: Peptimmune Completes Ph 1b Study of PI-2301

Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ — Peptimmune, Inc., a privately held [...]

• Caroline says: Peptimmune, a biotech company in Cambridge, MA will present the results from its Phase 1b study of PI-2301 in patients with secondary progressive MS. The studies thus far have been small and this drug is very far away from hitting pharmacy shelves near you, but the results look hopeful so far.
   

• Product Overview – DIRUCOTIDE

  Product Overview – DIRUCOTIDE Dirucotide (formally named MBP8298) is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a [...]

  • Caroline says: Read more about BioMS Medical Corp's dirucotide for SPMS. It's high science, but interesting.
     
  
  

  • SPMS Treatment Update: Spotlight on dirucotide (BioMS Medical Corp.)

    BioMS Medical Announces 2008 Year End Results Edmonton, Alberta, March 17, 2009 – BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis [...]

    • Caroline says: I think this is very positive news for people with SPMS because up until now, many of the therapies have been approved for, and more importantly, only WORK for those with RRMS. This is an encouraging update. They have initiated Phase III trials!